[{"orgOrder":0,"company":"Evive Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efbemalenograstim alpha","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Evive Biotech \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Aurobindo Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Benegrastim","moa":"","graph1":"Hematology","graph2":"Phase III","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Evive Biotech \/ Evive Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Evive Biotech \/ Evive Biotech"},{"orgOrder":0,"company":"Evive Biotech","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"Evive Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Evive Biotech \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"Evive Biotech \/ Nona Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by Evive Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims to accelerate the process of antibody discovery and drug development based on the Harbour Mice® antibody technology platform of Nona Biosciences.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          December 10, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Nona Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Under the terms of the agreement, Evive will be responsible for the ongoing development, manufacturing, registration, and supply of Ryzneuta (benegrastim), while Acrotech will use its sales and commercialisation capabilities to market and distribute the ...

                          Brand Name : Ryzneuta

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 23, 2022

                          Lead Product(s) : Benegrastim

                          Therapeutic Area : Hematology

                          Highest Development Status : Phase III

                          Recipient : Aurobindo Pharma Limited

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Safety and efficacy endpoints met successfully in pivotal trial for F-627 (efbemalenograstim alfa), a novel long-acting G-CSF . F-627 has proven that it is at least as efficacious and safe as NEULASTA®, which is the current standard of care.

                          Brand Name : F-627

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          July 08, 2020

                          Lead Product(s) : Efbemalenograstim alpha

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank